Loading...
Market
What will be the primary reason for choosing FluMist over traditional flu vaccines by end of 2024?
2
Resolution / Starting Odds
Convenience • 25%
Cost • 25%
Fear of needles • 25%
Effectiveness • 25%
Consumer surveys or market research reports
Story
FDA Approves AstraZeneca's FluMist, First At-Home Flu Vaccine for Self-Administration
Sep 20, 2024, 06:40 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first influenza vaccine that does not require administration by a healthcare provider. The approval covers individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. FluMist, designed for the prevention of influenza caused by virus subtypes A and B, will be available through third-party pharmacies, where individuals can complete a screening and eligibility assessment when ordering the vaccine.
View original story
Similar markets
Convenience • 25%
Fear of needles • 25%
Cost • 25%
Other • 25%
Self-administration nasal spray • 25%
Traditional injection • 25%
Pharmacy-administered nasal spray • 25%
Other methods • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Yes • 50%
No • 50%
Very Satisfied • 25%
Satisfied • 25%
Neutral • 25%
Dissatisfied • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
Prevention of hospitalization • 25%
Employer or insurance requirements • 25%
Public health campaigns • 25%
Other • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%